Lawrence Berkeley National Laboratory
Recent Work

Title
From Ancient Pathways to Aging Cells - Connecting Metabolism and Cellular Senescence

Permalink
https://escholarship.org/uc/item/2pd1334b

Journal
Cell Metabolism, 23(6)

ISSN
1550-4131

Authors
Wiley, CD
Campisi, J

Publication Date
2016-06-14

DOI
10.1016/j.cmet.2016.05.010

Peer reviewed
From Ancient Pathways to Aging Cells—Connecting Metabolism and Cellular Senescence

Christopher D. Wiley1,2,* and Judith Campisi1,2,*
1Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA
2Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA
*Correspondence: cwiley@buckinstitute.org (C.D.W.), jcampisi@buckinstitute.org (J.C.)
http://dx.doi.org/10.1016/j.cmet.2016.05.010

Cellular senescence is a complex stress response that permanently arrests the proliferation of cells at risk for oncogenic transformation. However, senescent cells can also drive phenotypes associated with aging. Although the senescence-associated growth arrest prevents the development of cancer, and the metabolism of cancer cells has been studied in depth, the metabolic causes and consequences of cellular senescence were largely unexplored until recently. New findings reveal key roles for several aspects of cellular metabolism in the establishment and control of senescent phenotypes. These discoveries have important implications for both cancer and aging. In this review, we highlight some of the recent links between metabolism and phenotypes that are commonly associated with senescent cells.

Introduction

Cellular senescence is a multifaceted process that radically alters the phenotype of metazoan cells that have the ability to divide. Two hallmarks of cellular senescence are an essentially irreversible arrest of cell proliferation and the development of a multi-component senescence-associated secretory phenotype (SASP). Both features are induced in response to a variety of stresses and physiological signals and can have beneficial or deleterious effects on the organism, depending on the context.

Many of the stresses that induce a senescence response cause genomic or epigenomic damage—or metabolic deficits—all of which can put cells at risk for oncogenic transformation (Campisi and d’Adda di Fagagna, 2007). Thus, the senescence arrest protects organisms from developing cancer. In addition, the SASP can optimize certain physiological processes, such as wound healing and the formation of specific embryonic structures (Muñoz-Espin and Serrano, 2014).

Senescent cells have been shown to accumulate with age in many tissues of vertebrate organisms (Adams, 2009; Campisi, 2013). In contrast to apoptotic and quiescent cells, senescent cells are highly metabolically active. Indeed, continued cell enlargement in the absence of cell division is a hallmark of senescent cells, suggesting an uncoupling of signals that link cell proliferation to cell size. The high metabolic activity of senescent cent cells was linked to increases in adenosine diphosphate (ADP) and adenosine monophosphate (AMP) relative to adenosine triphosphate (ATP) (Figure 1), and addition of exogenous mononucleotides (e.g., AMP) to the medium was shown to result in a senescence arrest. Subsequent studies identified several markers of increased glycolysis in conditioned media from senescent fibroblasts (James et al., 2015), further linking these processes and suggesting that this metabolic shift is a potentially important attribute of senescent cells. Indeed, in a murine lymphoma model of chemotherapy-induced senescence, blockade of glucose utilization resulted in regression of the tumor mass and improved treatment outcomes (Dörr et al., 2013), presumably due to the elimination of senescent tumor cells and their

General Metabolic Features of Senescent Cells

Decades ago, Otto Warburg observed that cancer cells generally differ from normal cells by the manner in which they metabolize glucose (Warburg, 1956). Cancer cells often elevate glycolysis over mitochondrial oxidative phosphorylation, even in the presence of high (atmospheric) oxygen. This “aerobic glycolysis” has been studied extensively for its role in tumor promotion in the decades since its discovery (Gatenby and Gillies, 2004; Kim and Dang, 2006; Vander Heiden et al., 2009). However, the study of glycolysis and other aspects of metabolism have only recently begun to be studied in the context of tumor suppression responses, such as cellular senescence. These new findings demonstrate how cancer, senescence, and aging can be linked in part through common metabolic processes.

It has been known for more than 30 years that as human fibroblast cultures accumulate senescent cells during serial passage, they gradually adopt a more glycolytic state (Bittles and Harper, 1984). Increased glycolysis has since been repeatedly associated with senescent cells in culture. Later, metabolic profiling similarly showed a significant shift to a more glycolytic state, but also a less energetic state, as cell cultures underwent replicative senescence (Zwerschke et al., 2003). Further, the senescent state was linked to increases in adenosine diphosphate (ADP) and adenosine monophosphate (AMP) relative to adenosine triphosphate (ATP) (Figure 1), and addition of exogenous mononucleotides (e.g., AMP) to the medium was shown to result in a senescence arrest. Subsequent studies identified several markers of increased glycolysis in conditioned media from senescent fibroblasts (James et al., 2015), further linking these processes and suggesting that this metabolic shift is a potentially important attribute of senescent cells. Indeed, in a murine lymphoma model of chemotherapy-induced senescence, blockade of glucose utilization resulted in regression of the tumor mass and improved treatment outcomes (Dörr et al., 2013), presumably due to the elimination of senescent tumor cells and their
AMP-activated protein kinase (AMPK) is a master regulator of cellular responses to energy stress. AMPK responds to increased AMP:ATP and ADP:ATP ratios, which activate AMPK-activated protein kinase (AMPK). AMP kinase in turn activates p53, which increases p21 transcription. AMPK also inactivates HuR, which increases the stability of the p21 and p16INK4a mRNAs; p21 and p16INK4a are cyclin-dependent kinase inhibitors that impose the senescence proliferative arrest by increasing activity of the pRB tumor suppressor. p53 and pRB might counterbalance each other in regulating glycolysis in senescent cells.

SASP, which can promote inflammation and the proliferation of tumor cells that escape the chemotherapy-induced senescence. Together, these studies suggest a functional link between a more highly glycolytic state and senescent phenotypes.

How might this metabolic shift drive senescence? AMP-activated protein kinase (AMPK) is a master regulator of cellular responses to energy stress. AMPK responds to increased AMP:ATP and ADP:ATP ratios (Figure 1) by activating a compensatory series of responses including fatty acid oxidation (FAO; also termed β-oxygenation), inhibition of fatty acid synthesis, increased mitochondrial biogenesis, and stimulation of glucose uptake (Hardie et al., 2012). AMPK activation can induce cell-cycle arrest and ultimately senescence through two distinct mechanisms (Figure 1). First, AMPK directly phosphorylates p53 on multiple residues, most notably on serine 15 (Jones et al., 2005). This p53 residue is also phosphorylated by ATM in response to genotoxic stress (Abraham, 2001) and is required for its activation and ability to arrest the cell cycle through transcriptional upregulation of the p21 cyclin-dependent kinase inhibitor. Indeed, AMPK itself is activated (phosphorylated) in an ATM-dependent manner in response to genotoxic stress (Luo et al., 2013). Second, AMPK also inhibits Hu antigen R (HuR)-dependent degradation of the mRNAs encoding the p21waf1 and p16INK4a cyclin-dependent kinase inhibitors, thereby resulting in a senescence arrest of cell proliferation (Figure 1) (Wang et al., 2003). Thus, AMPK acts as a bioenergetic sensor, mediating a metabolic checkpoint during energy stress that can ultimately result in senescence.

Beyond establishing the proliferative arrest of senescent cells, p53 also plays an important role in the regulation of glycolysis (Kruiswijk et al., 2015; Puzio-Kuter, 2011). First, p53 antagonizes the uptake of glucose by lowering expression of the glucose transporters GLUT1 and GLUT4 (Schwartzenberg-Bar-Yoseph et al., 2004). Second, p53 transcriptionally activates the expression of TP53-inducible glycolysis and apoptosis regulator (TIGAR), which dephosphorylates fructose-2,6-bisphosphate to antagonize the early stages of glycolysis (Bensaad et al., 2006). Third, p53 inhibits phosphoglycerate mutase (PGM), slowing the rate at which glucose is converted into pyruvate, thereby promoting senescence (Kondoh et al., 2005). Fourth, p53 binds glucose-6-phosphate dehydrogenase (G6PDH), inhibiting its activity and, consequently, the pentose phosphate pathway (PPP) (Jiang et al., 2011). Finally, p53 promotes mitochondrial oxidative phosphorylation by inducing expression of synthesis of cytochrome c oxidase 2 (SCO2) and inhibiting pyruvate dehydrogenase kinase 2 (PDK2) through Parkin (PARK2) activation (Matoba et al., 2006; Zhang et al., 2011). Together, these activities of p53 antagonize glycolysis and promote mitochondrial respiration. Thus, p53 likely acts to limit the glycolytic activity of senescent cells (Figure 1). Notably, p53 also limits the extent of the SASP (Coppé et al., 2008), suggesting the SASP is at least partly regulated by glycolysis.

**Pyruvate Metabolism and Senescence**

Pyruvate is a key metabolite at the crossroads of glycolysis and mitochondrial respiration. As a net effect of glycolysis, two molecules of ATP and two molecules NAD+ are converted to NADH, and two molecules of pyruvate are produced (Lehninger et al., 2013). Pyruvate itself is active in multiple metabolic processes. As cells shift to a glycolytic phenotype, as described for senescent cells (James et al., 2015; Zwerschke et al., 2003), pyruvate and NADH become available substrates for lactate dehydrogenase, producing NAD+ and lactate. Lactate is then excreted. Because NADH is produced by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) early during glycolysis, excess NADH can inhibit GAPDH and therefore become rate limiting for glycolysis. Pyruvate also serves as the primary carbon source for acetyl-coenzyme A (acetyl-CoA), which ultimately enters the tricarboxylic acid (TCA) cycle (Lehninger et al., 2013). This way, mitochondria generate much of their energy via pyruvate metabolism. Whether pyruvate becomes lactate or enters the TCA cycle is determined by phosphorylation of pyruvate dehydrogenase (PDH), which catalyzes the formation of acetyl-CoA from pyruvate; this decision determines whether a cell senesces in response to activated oncogenes (Kaplon et al., 2013). Thus, pyruvate metabolism is key to determining whether a cell can generate sufficient energy via glycolysis upon becoming senescent.

Excessive reactive oxygen species (ROS) can induce a senescence response (Ziegler et al., 2015), and pyruvate also helps scavenge ROS. Pyruvate interacts with hydrogen peroxide (H2O2) to form acetate, CO2, and H2O, thereby contributing to cellular antioxidant defenses (Desager et al., 1997). It is unclear how important the antioxidant properties of pyruvate are in senescent cells. Ironically, superphysiological (millimolar) concentrations of pyruvate actually decrease the replicative lifespan
Malate is another key metabolite that regulates senescence. Malate is produced from fumarate by fumarase, and is decarboxylated to pyruvate and CO₂, through reduction of either glutamic-oxaloacetic transaminase 1 (GOT1), a malate-aspartate shuttle enzyme, decreases the cytosolic NAD⁺/NADH ratio, leading to AMPK activation. AMPK in turn phosphorylates and activates p53, which promotes senescence but suppresses the IL1R signaling arm of the SASP. Malate dehydrogenase (MDH1) and GOT1 are required for the synthesis of aspartate following ETC inhibition, and loss of either enzyme prevents pyruvate from rescuing cellular proliferation.

Mitochondrial Dysfunction-Associated Senescence

Multiple mitochondrial manipulations—loss of the mitochondrial sirtuins SIRT3 or SIRT5 or the mitochondrial chaperone HSPA9, inhibition of the ETC by rotenone or antimycin, or depletion of mitochondrial DNA—induce a senescence response. Unlike genotoxic stress or oncogene activation, mitochondrial dysfunction induces a distinct SASP that lacks key proinflammatory factors (Wiley et al., 2016) that depend on interleukin 1 receptor (IL1R) signaling (Ojulaval, 2009). Mitochondrial dysfunction-associated senescence (MiDAS) illustrates the plasticity of the SASP. Notably, pyruvate not only prevents the MiDAS growth arrest, but also restores the IL1R-dependent arm of the SASP. MiDAS cells have a decreased NAD⁺/NADH ratio; addition of pyruvate (Wiley et al., 2016) restores this ratio, decreases the ADP/ATP ratio, restores aspartate synthesis (Birsoy et al., 2015), and promotes cell proliferation (Figure 2).

Like the loss of malic enzymes (Jiang et al., 2013), MiDAS activates AMPK, resulting in p53 activation and senescence (Figure 1). This p53 activity in turn inhibits the transcription factor NF-κB (Wiley et al., 2016), a major regulator of the SASP (Freund et al., 2011). Thus, metabolic regulation of p53 during mitochondrial dysfunction controls two aspects of the senescence response (growth arrest and the SASP). Senescent cells accumulate in at least three murine models of mitochondrial dysfunction and premature aging (Kang et al., 2013; Velarde et al., 2012; Wiley et al., 2016), implicating mitochondrial dysfunction as a driver of cellular senescence in vivo.

Mitochondrial mass and DNA (mtDNA) content increase 2- to 3-fold in senescent cells (Correa-Melo et al., 2016), and elimination of either mtDNA or mitochondria antagonizes the senescence arrest and SASP. Increased mitochondria, generally driven by mTOR (mechanistic target of rapamycin) signaling (discussed below), can increase ROS and DNA damage. Indeed, lowering mitochondrial mass in senescent cells not only lowers mitochondrial ROS, as expected, but also 53BP1 foci (a marker of DNA double-strand breaks [DSBs] and DNA damage response [DDR] signaling) (Correa-Melo et al., 2016), which is required for the arrest and IL1R arm of the SASP (Rodier et al., 2009). Thus, expansion of mitochondria in senescent cells might reinforce senescent phenotypes by promoting DDR signaling.

Many questions remain unanswered. For example, although reducing mitochondria in senescent cells decreases both ROS and 53BP1 foci (Correa-Melo et al., 2016), increased ROS in some forms of mitochondrial dysfunction does not always increase 53BP1 foci or DDR signaling. Thus, ROS may not be an obligate driver or reinforcer of senescent phenotypes. Likewise,
it is not clear which factors drive the MIDAS SASP, nor the extent to which MIDAS occurs during natural aging. By contrast, much more is known about the role of NAD metabolism in senescence and aging.

**Role of NAD Metabolism in Senescent Phenotypes**

As described above, low NAD+/NADH ratios promote cellular senescence (Figure 2) at least in part by limiting glycolysis and ATP production. Likewise, NADP+/NADPH ratio controls cellular redox status, but NAD+ can regulate cellular homeostasis and senescence independently of NADH or NADPH. NAD+ is the primary ADP-ribose donor for poly-ADP ribose polymerase (PARP), a major mediator of DNA repair in response to genotoxic stress (Kim et al., 2005). PARP inhibition promotes DNA damage in irradiated tumor cells, sensitizing them to senescence (Efimova et al., 2010). In addition, PARP-1 is required for NF-κB activation and the proinflammatory SASP in melanoma cells (Ohanna et al., 2011). Thus, low NAD+ promotes senescence. Indeed, nicotinamide mononucleotide phosphoribosyltransferase (NAMPT) inhi-

Together, these studies show that both senescence and the SASP are subject to metabolic control. On one hand, senescence appears to be a stress checkpoint that guards against metabolic crisis and potential oncogenesis. On the other, senescence due to metabolic stress may be accompanied by its own set of secreted molecules (as in MIDAS) and thus have unique effects on tissue microenvironments. Understanding these pathways can provide new therapeutic targets for the treatment of maladies associated with senescence, ranging from cancer to aging and age-related diseases.

**Metabolic Features of Oncogene-Induced Senescence**

Activation of several proto-oncogenes induces a senescence response as a mechanism to protect against cancer (Courtice-Cox et al., 2008). Metabolic changes have been studied in the context of oncogenesis for some time, but only recently has metabolism been studied in the context of oncogene-induced senescence (OIS) and other forms of senescence (Figure 3).

**Skewed Balance between Glycolysis and Oxidative Phosphorylation**

OIS entails a key shift in the metabolism of pyruvate (Kaplon et al., 2013). Human fibroblasts transformed with BRAFV600E, a common oncogenic mutation and inducer of senescence, undergo several metabolic changes, including increased oxygen consumption, increased release of glutamate, and decreased pyruvate secretion. These changes are associated with decreased phosphorylation of PDH, which catalyzes the conversion of pyruvate into acetyl-CoA, allowing it to enter the TCA cycle. The decline in PDH phosphorylation results from increased expression of pyruvate dehydrogenase phosphatase (PDP2) and decreased levels of pyruvate dehydrogenase kinase (PDK1). Phosphorylation of PDH inhibits its activity, so the net effect of these alterations is increased TCA cycle activity and mitochondrial respiration. Further, PDP2 depletion or PDK1 overexpression allows BRAFV600E-expressing cells to bypass senescence. PDK1 overexpression also potentiates malignant transformation of BRAFV600E-expressing melanocytes, while PDK1 depletion suppresses transformation. Since the ETC is a major source of ROS, mitochondria-derived oxidative stress might drive OIS. Alternatively, since anaerobic fermentation of pyruvate into lactate is required to maintain NAD+/NADH ratios under high glycolytic activity, reduced deoxynucleotides (discussed below) may partially explain how shunting pyruvate to mitochondria drives OIS in melanocytes and how a metabolic switch to a more glycolytic phenotype allows escape from senescence (Aird et al., 2013). Thus, a tradeoff between glycolysis and mitochondrial metabolism can control senescence in response to oncogene activation.

**Deoxynucleotide Synthesis**

Recent studies implicate the loss of deoxynucleotide synthesis in RAS-induced senescence (Aird et al., 2013). Oncogenic RAS lowers the mRNA and protein levels of ribonucleotide reductase (RRM2), which catalyzes the formation of deoxyribonucleotide diphosphates from ribonucleotide diphosphates. The depletion of deoxynucleotides causes replication forks to stall and eventually collapse, which is exacerbated by the stimulation of cell proliferation caused by oncogenic RAS. The resulting DNA DSBs elicit a senescence response. RRM2 overexpression can rescue OIS, whereas RRM2 depletion induces senescence (Aird et al., 2013).
Further, RRM2 is downregulated in human benign nevi, which are often composed of senescent melanocytes (Salama et al., 2014), and is often overexpressed in human melanoma. Thus, nucleotide metabolism also plays a key role in senescent phenotypes, at least in the context of oncogene activation. Of additional interest, ATM deficiency allows RRM2-depleted cells to proliferate, reduces the incidence of stalled replication forks and DNA damage markers, and rescues the depletion of deoxy-nucleotides (Aird et al., 2015). ATM deficiency also increases glycolysis and—more specifically—the pentose phosphate pathway, which provides nucleotide precursors.

**Retinoblastoma Protein and Regulation of Glycolysis**

The tumor suppressor and transcriptional regulator retinoblastoma protein (RB) mediates a second major pathway that promotes the senescence arrest and also mediates metabolic changes in OIS. While p53 antagonizes glycolysis in favor of mitochondrial oxidation of pyruvate and fatty acids, RB stimulates glycolysis in OIS (Takebayashi et al., 2015). RB also promotes mitochondrial oxidative phosphorylation, either by regulating or complementing the activity of PDH1, which promotes mitochondrial catabolism of pyruvate produced by elevated glycolysis. RB-mediated mediated metabolic changes might regulate the senescence growth arrest by counterbalancing the inhibition of glycolysis by p53 (Figure 1). By contrast, RB activation by its upstream positive regulator p16^{INK4a} is not sufficient for induction of a SASP (Coppé et al., 2011).

**Role of Fatty Acid Metabolism**

OIS is also linked to increased FAO (Quijano et al., 2012). Upon induction of senescence by oncogenic RAS, human fibroblasts increase oxygen consumption, while steady-state levels of many fatty acids significantly decline. Inhibition of carnitine palmitoyltransferase (CPT1A) prevents the transfer of fatty acids into the mitochondria, which in turn prevents the increases in oxygen consumption. In accordance with this decrease in mitochondrial activity, much of the proinflammatory SASP is reduced. Thus, much like the case of MIDAS (Wiley et al., 2016), the bioenergetic state of the senescent cell strongly influences the proinflammatory arm of the SASP.

RAS-induced senescence is also linked to increased activity of arachidonate 5-lipoxygenase (ALOX5), which catalyzes the first step in the synthesis of several signaling lipids, including resolvins and leukotrienes (Catalano et al., 2005). In turn, overexpression of ALOX5 induces p53-dependent senescence. This senescence is not a consequence of leukotriene synthesis per se; rather, the elevated ROS produced by ALOX5 activity appears to be causal (Catalano et al., 2005). Little is known about the role of ALOX5 in the SASP, but leukotrienes are known to mediate inflammation and thus may themselves be SASP components.

**Proteostasis in Senescence**

Senescent cells also display alterations in protein metabolism that can influence both the growth arrest and SASPs. There are two major ways in which cellular proteostasis is altered in senescent cells. First, accelerated degradation lowers the levels of proteins that antagonize senescent phenotype. Second, alterations in translational efficiency change levels of senescence-associated proteins.

**Autophagy and Protein Damage**

Multiple lines of evidence indicate a senescence-associated increase in autophagy, especially macroautophagy, the process by which protein complexes and organelles associate with membrane-bound autophagosomes that eventually fuse with lysosomes (Capparelli et al., 2012; Gamerdinger et al., 2009; Singh et al., 2012). In endothelial cells, activation of autophagy determines whether glycated collagen-induced stress results in senescence or cell death, although this determination may be due to autophagy of damaged lipids, rather than proteins (Patschan et al., 2008). Conversely, inhibition of autophagy predisposes cells to senescence (Kang et al., 2011; Wang et al., 2012). Recent evidence also links senescence-inducing genotoxic stress and ATM/ATR activation to the SASP through autophagy (Kang et al., 2015). In this case, loss of selective autophagy by p62/SQSTM1 stabilizes GATA4, which then induces transcription of a subset of SASP factors, including IL1A. Thus, although macroautophagy is elevated during senescence, loss of specific autophagic programs is essential for development of the SASP.

Autophagic degradation of damaged organelles and proteins occurs in the lysosome, a membrane-bound organelle that serves as a recycling center for cells. In agreement with activation of autophagy, there is also evidence for altered lysosomal activity in senescent cells. Indeed, the senescence-associated β-galactosidase, a canonical marker of senescent cells, is a lysosomal protein (Lee et al., 2006). In addition, following induction of senescence, chromatin fragments bud from the nucleus, enter the cytoplasm, and are processed by lysosomes, resulting in a gradual depletion of total histone content (Ivanov et al., 2013). In addition, associations between the autophagy-regulating kinase mTOR and the lysosome occur at senescence, and disruption of this association prevents the synthesis of certain SASP factors (Narita et al., 2011). Lysosomes therefore play an important role in the senescent phenotype.

A second protein degradation complex, the proteasome, also changes in senescence. Senescent cells elevate selective proteasome activity; this senescence-associated protein degradation (SAPD) reduces the levels of selected proteins required for cell cycle progression, mitochondrial function, and RNA processing (Deschénes-Simard et al., 2013). Inactivation of individual SAPD targets is sufficient to induce senescence, confirming a role for the proteasome in senescence.

Proteins are targeted to the proteasome via the activity of ubiquitin-conjugating enzymes, many of which play key roles in senescence. For example, mouse double minute 2 (MDM2), a ubiquitin-conjugating enzyme, targets p53 for degradation, and its inhibition can drive senescence (Efeyan et al., 2007).
MDM2 also antagonizes glycolysis and promotes senescence by targeting PGM for degradation (Mikawa et al., 2014). Protein ubiquitination states change notably with senescence, most notably in proteins responsible for regulating translation, including several eukaryotic initiation factors (eIFs), elongation factors, ribosomal subunits, and mTOR signaling complexes (Bengsch et al., 2015). The mitochondrial ubiquitin ligase March5 antagonizes senescence (presumably MIDAS) by promoting degradation of mitofusin 1 and dynamin-regulated protein 1 (DRP1) (Park et al., 2010). Additionally, ubiquitin-conjugating enzymes can be targeted to proteins in a senescence-specific manner. For example, speckle-type POZ protein (SPOP) is an adaptor protein that targets SENP7 (a desumoylase) for degradation in response to oncogene activation. Loss of SENP7 results in epigenetic changes that promote senescence (Zhu et al., 2015). SPOP is elevated during OIS, and overexpression of SPOP drives senescence, whereas knockdown of SPOP allows cells to escape OIS. Together, these studies confirm that protein degradation, whether from autophagy or the proteasome, plays an important role in senescent phenotypes.

**Protein Translation, Rapamycin, and Senescence**

A growing body of literature now links cellular senescence to drugs that extend lifespan in multiple species. One such drug is rapamycin, an inhibitor of the mTORC1 complex of the mTOR kinase and an inducer of autophagy. Rapamycin reduces the IL1R-driven arm of the SASP (Herranz et al., 2015; Laberge et al., 2015) by inhibiting the translation of IL-1α and MAPKAPK2, key mediators of the proinflammatory elements of the SASP. Rapamycin also prevents the increase in mitochondrial DNA, biomass, and ROS associated with genotoxic stress-induced senescence (Correia-Melo et al., 2016). Rapamycin or mTOR inhibition prevents 4EBP1 phosphorylation through a pathway that is also inhibited by metabolic stresses such as calorie restriction (Szytnicki et al., 2007; Zid et al., 2009). Since rapamycin and calorie restriction extend lifespan in many species (Bové et al., 2011; Harrison et al., 2009; Heilbronn and Ravussin, 2003), these findings suggest senescence as a potential link between the overlapping effects of rapamycin and caloric restriction.

Thus, protein translation is linked to senescence through both autophagy and translation. A key point of these studies is that these mechanisms are relatively easy to target. The links between lifespan extension through either calorie restriction or rapamycin and cellular senescence suggest mechanisms by which senescent phenotypes might be targeted for therapeutic intervention.

**Conclusions**

Recent advances have expanded our understanding of the interface between metabolism, cell signaling, and cell fates, particularly cellular senescence, which can drive a variety of age-related pathologies, including cancer. Our understanding of the metabolic reprogramming that occurs during cellular senescence (Figure 3) is still in infancy, so it is likely that many new findings will emerge in the near future.

Links between senescence and NAD metabolism have been suspected for some time, but now it is clear that both NAD+ levels and NAD+/NADH ratios control aspects of senescent phenotypes through different pathways. Recently, compounds that elevate NAD+, including nicotinamide riboside (NR), and P7C3, have been proposed as possible therapeutics for preventing several age-related pathologies (Gomes et al., 2013; Stein and Imai, 2014; Yoshino et al., 2011). Since elevating NAD+ can also increase the NAD+/NADH ratio, these compounds might prevent both MIDAS and other forms of senescence. A concern, however, is that restoring NAD+/NADH ratios in the context of mitochondrial dysfunction might also result in proliferation of cells with compromised mitochondria, as well as proinflammatory secretion that ultimately promotes tissue degeneration.

While the relationship between senescence and glycolysis has been confirmed in many studies, it less clear precisely why senescent cells become more glycolytic. Since senescent cells increase in size after arresting proliferation and the SASP demands considerable macromolecular biosynthesis, it is possible that senescent cells, like many cancer cells (Vander Heiden et al., 2009), favor glycolysis for its ability to provide precursors for a high demand for protein, lipid, and other cellular components.

What therapeutic outcomes might result from these discoveries? Given the complexities of metabolism in general, and the role of metabolism in regulating both the causes and consequences of the senescence response, the field is ripe for applications of systems biology approaches. Indeed, this approach was recently taken not only to understand the dynamics of the senescence response but also to identify therapeutic targets for ameliorating its deleterious effects (Dalle Pezze et al., 2014).

With the wealth of data now emerging, targeting the metabolic differences between non-senescent and senescent cells could become an important strategy for eliminating the deleterious effects of senescence. Indeed, metabolic targeting was a strategy used to eliminate senescent tumor cells following chemotherapy (Dörre et al., 2013). Similarly, metabolism-targeting drugs such as rapamycin or etomoxir can suppress the proinflammatory SASP (Laberge et al., 2015; Quijano et al., 2012), preventing one of the most detrimental aspects of senescence. Metabolism-targeted approaches therefore hold great promise for dealing with the complications that arise as a result of senescence, the most global of which is aging and its associated pathologies.

**REFERENCES**


